This article was originally published in The Gray Sheet
Issuing $200 mil. of notes, bearing an annual interest rate of 7.25%, to repay existing debt. The notes are due Feb. 15, 2008 and are priced at 99.728%. Underwriting the issue is First Boston Corporation; Goldman, Sachs; Merrill Lynch; and J. P. Morgan Securities. Baxter initiated two separate offerings of $150 mil. in notes in the fall of 1992 ("The Gray Sheet" Nov. 9, p. 20).
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.